WebApr 10, 2024 · Pear Therapeutics Inc. filed for bankruptcy protection under chapter 11 to buy time to sell its assets. The company was the first-to-market for prescription digital therapies, with three PDTs gaining regulatory nods from the FDA: Reset for substance use disorder, Reset-O for opioid use disorder and Somryst for insomnia. WebSomryst is a 9-week Prescription Digital Therapeutic (PDT) for chronic insomnia. Somryst can be used on a mobile device, ... Please instruct the patient to consult with their HCP if …
March 23, 2024 Pear Therapeutics, Inc. Yuri Maricich, MD, MBA …
WebIndications for Use. Somryst® is a prescription-only digital therapeutic intended to provide a neurobehavioral intervention (CBT-I) to patients 22 years of age and older with chronic insomnia. Somryst treats patients with chronic insomnia by improving a … WebMay 12, 2024 · Not much. Until now! Late last year, Pear Therapeutics released a CBT-i app (formerly “SHUT-i”, now “ Somryst ”) which holds the patient’s hand through the complicated CBT-i process. Studies show it works as well as a real therapist, which is very well indeed. There’s only one catch: you need a doctor’s prescription. thames abingdon
Pear Therapeutics Announces Data from Two Studies Evaluating ... - Benzinga
WebDec 9, 2024 · The company’s two substance abuse platforms, reSET and reSET-O, were the first PDTs ever to receive market authorization by the Food and Drug Administration, and its insomnia platform Somryst was also authorized this year, perhaps an indication that the tides of psychiatry are turning toward digitization. WebApr 4, 2024 · Science Communications Manager, Columbia University's Mortimer B. Zuckerman Mind, Brain, and Behavior Institute 1 mgg WebMar 15, 2024 · Interim data from DREAM, a fully virtual, decentralized study, found treatment with Somryst® achieved significant and meaningful reductions in insomnia severity through six months1 Results ... thames aerial services